For how we live.
In the GSK-funded phase 3 MATINEE trial, the anti-IL-5 antibody lowered moderate or severe exacerbations from 1.01 to 0.80 a year — but symptom and quality-of-life endpoints showed no significant benefit.
In a phase 2 trial in people whose hidradenitis suppurativa had already failed anti-TNF drugs, two lutikizumab doses beat placebo at 16 weeks. A third did not, and the placebo response was high.
A pooled analysis of four trials found depemokimab roughly halved exacerbations, yet it did not significantly improve asthma control or reach the threshold for a meaningful quality-of-life gain.
REPLENISH randomised 381 patients with relapsed polymyalgia rheumatica. Sustained remission at 52 weeks reached about 41% on secukinumab versus 20.4% on placebo. Novartis funded the trial.
Wellness marketing says reconnecting to the Earth's electrons lowers cortisol, inflammation and pain. The human studies are small, mostly unblinded, and largely produced by the idea's own advocates.
Sugars bond to proteins to form advanced glycation end products that accumulate with age and stiffen tissue. Low-AGE diets nudge metabolic markers, but no trial shows they slow ageing.
Immunosenescence, the age-related decline of immunity, is real: the thymus shrinks and the T-cell repertoire narrows. The proven counter is not a supplement but vaccines engineered to force a response.
Two trials found low-dose colchicine cut cardiovascular events, and the FDA approved it for heart risk in 2023. Then the largest trial found nothing, leaving the question genuinely unsettled.
The rise in chronic, low-grade inflammation with age is genuine, and researchers built a clock from it. The one large trial that lowered inflammation for a hard outcome treated heart disease, not ageing.
A single-centre randomised trial found that three cycles of intravenous immunoglobulin on top of high-dose steroids improved muscle disease faster and further — in just 44 patients, at one Dutch hospital.
Small trials suggest curcumin can modestly reduce arthritis pain, sometimes on par with painkillers — but the evidence is thin, and turmeric supplements are linked to a rising number of serious liver injuries.
A 2013 paper named nine hallmarks of aging; a 2023 update made it twelve. The framework is the field's shared map — but critics argue it describes ageing without explaining it.
Tozorakimab, which blocks interleukin-33, lowered the rate of moderate or severe COPD exacerbations by about a third against placebo, without an eosinophil requirement to qualify.
Animal studies show plastic particles disturbing the gut and triggering inflammation. Human evidence is mostly detection, with cause and effect still unresolved.
A systematic review of the randomised trials found no compelling evidence for any remedy. Newer work suggests the hangover is driven by inflammation and metabolites, not just dehydration.
A trial of an anti-inflammatory antibody cut cardiovascular events without changing lipids. A genetic study of 194,418 people found the inflammation marker everyone measures is not itself causal.
Three 2025 reviews of the same drugs reach three answers: a matched cohort finds less cardiovascular disease on biologics, a network meta-analysis flags one drug as raising events, and 43 trials find nothing.
It found rising microbiome diversity and falling inflammatory markers in the fermented-food arm — and no change in its own primary outcome in the high-fibre arm it was compared against.
Two large trials of the anti-ST2 antibody gave discordant results: a modest signal in the phase 2b study, and a missed primary endpoint for the same dose in the confirmatory phase 3.
In a single-centre trial of 100 patients with decompensated cirrhosis, six months of atorvastatin cut recurrent complications from 72% to 36% — a striking but preliminary result needing larger confirmation.
The trial's own primary outcome — inflammation — was flat. What the new analysis adds is a molecular account of why the fat loss did not translate into the benefits fasting is sold on.
October brought pooled analyses of ginger and of marine omega-3s. Both report significant effects on blood markers. Neither measured whether anyone got healthier.